
    
      Investigation of the long-term efficacy and safety of Depigoid Birch 5000 according to the
      perennial treatment regimen in comparison to placebo in adult and adolescent patients with
      birch pollen-induced allergic rhinitis and/or rhinoconjunctivitis to show superiority vs.
      placebo.

      As the study includes adolescent patients it is run under an approved PIP.

      Total study duration per patient will be 5 years: 3 years of perennial treatment (application
      of study medication at intervals of 4-6 weeks) followed by a treatment-free observational
      phase of 2 years (seasons).
    
  